
ASRT Stock Forecast & Price Target
ASRT Analyst Ratings
Bulls say
Assertio Hldgs is expected to continue seeing growth in their revenue streams from both research and service sales, reaching $2,100 in the latest quarter. With a strong focus on meeting the needs of patients in the oncology market, coupled with the potential acquisition by Garda Therapeutics for $21.80 per share, the company faces minimal risks in its growth and potential legal risks as well.
Bears say
Assertio Hldgs is facing challenges due to its reliance on legacy products with limited market exclusivity and divestment of these assets for a low multiple of its one-year sales, leading to a decreased revenue stream. The term sheet for the acquisition of Assertio by Garda includes a "window-shop" period, which may lead to a higher offer from other potential buyers, but given the limited upside potential for Assertio's products, it is unlikely that a higher offer will emerge. Risks to the price target include potential delays or termination of the transaction, but the undisclosed contingent value right (CVR) is not expected to have a significant impact on the consideration for Assertio shareholders.
This aggregate rating is based on analysts' research of Assertio Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.
ASRT Analyst Forecast & Price Prediction
Start investing in ASRT
Order type
Buy in
Order amount
Est. shares
0 shares